Bill · H.R. 5736· House(119-HR-5736)
PAVE Act
- Introduced
- 10/10/2025
- Last activity
- 10/10/2025 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- H. Griffith
- Cosponsors
- - 4 - 5
- Introduced
- In Committee
What this bill would do
This bill, known as the "Penicillin Allergy Verification and Evaluation Act" or the "PAVE Act," seeks to amend the Social Security Act. It aims to include penicillin allergy verification and evaluation as part of the Medicare program's initial preventive physical examination. The bill also includes these evaluations in annual wellness visits. The process involves identifying individuals with a reported history of penicillin allergy and determining if that history is consistent with an actual allergy. It also includes providing information on the health impacts of these labels and making referrals to specialists when appropriate. These changes are intended to take effect on January 1, 2027.
Yes· 3 of 6
Would people over 65 be better off under this?+5
The bill provides Medicare beneficiaries with verification of penicillin allergies to improve health outcomes and reduce mortality risks.
Would retired people be better off under this?+5
The bill enhances preventive care services included in Medicare annual wellness visits for retirees.
Does this make health care easier to get in general?+4
The bill improves access to allergy and immunology specialists through Medicare referrals.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Improved Health Outcomes: The bill aims to address issues where a penicillin allergy label is associated with increased hospital length of stay, increased perioperative infections, and increased mortality (Section 2, Paragraph 4).
-
Accurate Medical Records: The bill facilitates the identification of individuals who may be able to safely take penicillin after verification testing, noting that over 90 percent of those with a self-reported allergy can safely take it (Section 2, Paragraph 2).
-
Verification and Specialist Access: Under the new provisions, Medicare patients will receive verification and evaluation that includes checking if a reaction is a true allergy, providing information on the impact of these labels, and offering referrals to allergy or immunology specialists (Section 3, Subsection a).
-
Cost Savings: The bill notes that penicillin allergy evaluation has been shown to be a cost-saving intervention (Section 2, Paragraph 5).
Potential Negative Impacts for People
- No negative impacts or burdens are explicitly stated in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Retirees+5Good For Seniors+5Good For Low Income Households+2
- Healthcare
- Improves Healthcare Access+4Increases Medicare Funding+2
- Economy And Finance
- Reduces Government Spending+3
- 6/22/2026
- 1 Cosponsor added.
- 5/7/2026
- 1 Cosponsor added.
- 10/21/2025
- 1 Cosponsor added.
- 10/10/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 6 Cosponsors added.
- Introduced in House
Jake AuchinclossDemocrat · Massachusetts
Ami BeraDemocrat · California
Don BaconRepublican · Nebraska
Suzan DelBeneDemocrat · Washington
Gregory MurphyRepublican · North Carolina
Mariannette Miller-MeeksRepublican · Iowa
Robert OnderRepublican · Missouri
Kim SchrierDemocrat · Washington
Eugene VindmanDemocrat · Virginia